Baseline patient and lesion characteristics of registry studies
| Mattesini et al16 | Gori et al15 | Sato et al11 | Cortese et al12 | BVS-EXAMINATION13 | Costopoulos et al14 | |
|---|---|---|---|---|---|---|
| Patients (n) | 73 | 253 | 192 | 563 | 580 | 184 |
| BVS (n) | 35 | 150 | 96 | 122 | 290 | 92 |
| DES (n) | 38 | 103 | 96 | 441 | 290 | 92 |
| Male (%) | 79 | 72 | 89 | 78 | 80 | 87 |
| Mean age (years) | 62 | 62 | 66 | 59* | 57 | 63 |
| Diabetes (%) | 31 | 17 | 23 | 17 | 13 | 27 |
| Follow-up (months) | 8 | 6 | 12 | 8* | 12 | 6 |
| GPI use (%) | ||||||
| BVS | NR | 38.7 | NR | 34.8 | 67.5 | NR |
| DES | NR | 11.7 | NR | 37.4 | 51.7 | NR |
| DAPT duration (months) | NR | 12 | 12 | 12 | 12 | 12 |
| Device type | BVS, EES, ZES | BVS, EES | BVS, BES, EES | BVS, EES | BVS, EES | BVS, EES |
| Intracoronary imaging used (OCT/IVUS %) | ||||||
| BVS | 100 | NR | 91.7 | 4.4 | NR | 99.8 |
| DES | 100 | NR | 64.6 | 0.4 | NR | 16.8 |
| ACC/AHA lesion class (%) | ||||||
| A | 0 | NR | NR | NR | NR | NR |
| B1 | 0 | NR | NR | NR | NR | NR |
| B2 | 31 | NR | 84.1† | NR | NR | 80.8† |
| C | 69 | NR | NR | NR | ||
| Device predilation (%) | ||||||
| BVS | 100 | 100 | 100 | 94.1 | 81 | 97.8 |
| DES | 100 | 100 | 72.1 | 60 | 29 | 75.8 |
| Device postdilation (%) | ||||||
| BVS | 100 | 14 | 100 | 94.1 | 36.3 | 99.3 |
| DES | 100 | 14 | 86.4 | 37.9 | 15.2 | 77.4 |
| Expected maximum diameter of postdilation balloon (mm) | ||||||
| BVS | 3.5 | NR | 3.2 | 3.5 | NR | 3.2 |
| DES | 3.5 | NR | 3.15 | 3.5 | NR | 3.1 |
| Final dilation pressure (atm) | ||||||
| BVS | 21.3 | 15.3 | 21.1 | 10* | NR | 20.9 |
| DES | 17.1 | 12.2 | 18.4 | 14 | NR | 19.0 |
| Clinical presentation (%) | All-comers | |||||
| STEMI | 0 | 40.7 | 100 | 100 | 11.4‡ | |
| Non-STEMI | 0 | 41.8 | 0 | 0 | ||
| Unstable angina | 4.1 | 17.3 | 0 | 0 | ||
| Stable angina | 95.8 | 0 | 0 | 0 | 88.6 | |
| Silent ischaemia | 0 | 0 | 0 | 0 | 0 | |
Values are means unless otherwise specified or (%).
*Expressed as median.
†B2+C lesions.
‡Acute coronary syndrome.
BES, biolimus-eluting stent; BVS, bioresorbable vascular scaffold; DAPT, dual antiplatelet therapy; EES, everolimus-eluting stent; GPI, glycoprotein IIb/IIIa inhibitors; IVUS, intravascular ultrasound; NR, not reported; OCT, optical coherence tomography; STEMI, ST-elevation myocardial infarction; ZES, zotarolimus-eluting stent.